FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2098188679> ?p ?o ?g. }

• W2098188679 endingPage "539" @default.
• W2098188679 startingPage "535" @default.
• W2098188679 abstract "The long acting beta 2 agonist formoterol has proved to be an effective bronchodilator with a prolonged action of 12-14 hours. However, the precise role of formoterol in the maintenance treatment of asthma is still under debate. A study was performed to investigate the efficacy and safety of treatment with formoterol for six months in subjects with asthma.In a multicentre double blind, placebo controlled, parallel group study 239 subjects with mild to moderate asthma were randomly assigned to treatment with either inhaled formoterol 24 micrograms twice daily (n = 125) or placebo (n = 114) during eight months. The study consisted of a four week run in period, a 24 week treatment period, and a four week washout period. All subjects were using regular inhaled corticosteroids (100-3200 micrograms daily) but were still needing at least five inhalations of short acting beta 2 agonist per week for symptom relief. The study was performed in 10 outpatient clinics in Canada, and five outpatient clinics and one coordinating centre for 44 Dutch general practitioners in The Netherlands. Twice daily self-reported peak expiratory flow (PEF) measurements, symptom scores, and rescue beta 2 agonist use during the last 28 treatment days compared with baseline values were used as main outcome measures. Spirometric values were measured at entry, at the start of treatment, after four, 12 and 24 weeks of treatment, and after four weeks washout.One hundred and twenty five subjects received formoterol 24 micrograms twice daily via Turbohaler and 114 received placebo. Baseline FEV1 was 67.1% predicted and mean bronchodilator reversibility was 26%. The mean total asthma symptom score was 3.6 (maximum possible 21). A significant decrease in symptoms in favour of formoterol (difference from placebo -0.64, 95% CI -0.04 to -1.23, p = 0.04) was observed. Compared with placebo, morning PEF increased (difference from placebo 28 l/min, 95% CI 18.3 to 37.7, p = 0.0001) and the use of short acting beta 1 agonists decreased (daytime difference from placebo -1.1 inhalation, 95% CI -1.4 to -0.7, p = 0.0001) in the formoterol group. PEF returned to baseline following discontinuation of formoterol, as did asthma symptom scores. Thirty three patients treated with formoterol and 32 treated with placebo required treatment with prednisolone during the study (58 and 55 courses, respectively).Adding formoterol 24 micrograms twice daily by Turbohaler to inhaled corticosteroids was effective in improving symptom scores and morning PEF, and decreasing the use of rescue beta 2 agonists. There was no apparent loss of asthma control during 24 weeks of treatment with formoterol." @default.
• W2098188679 created "2016-06-24" @default.
• W2098188679 creator A5003864064 @default.
• W2098188679 creator A5006832289 @default.
• W2098188679 creator A5011519571 @default.
• W2098188679 creator A5030603878 @default.
• W2098188679 creator A5036017418 @default.
• W2098188679 creator A5044409997 @default.
• W2098188679 creator A5066056972 @default.
• W2098188679 creator A5084335551 @default.
• W2098188679 creator A5089109471 @default.
• W2098188679 creator A5091663221 @default.
• W2098188679 date "1997-06-01" @default.
• W2098188679 modified "2023-10-14" @default.
• W2098188679 title "Effects of the long acting beta agonist formoterol on asthma control in asthmatic patients using inhaled corticosteroids. The Netherlands and Canadian Formoterol Study Investigators" @default.
• W2098188679 cites W1572030781 @default.
• W2098188679 cites W1583903120 @default.
• W2098188679 cites W1965671865 @default.
• W2098188679 cites W1969153504 @default.
• W2098188679 cites W1990951259 @default.
• W2098188679 cites W2031867711 @default.
• W2098188679 cites W2049853440 @default.
• W2098188679 cites W2081835439 @default.
• W2098188679 cites W2084459895 @default.
• W2098188679 cites W2085246519 @default.
• W2098188679 cites W2087666617 @default.
• W2098188679 cites W2092597847 @default.
• W2098188679 cites W2098633046 @default.
• W2098188679 cites W2104154820 @default.
• W2098188679 cites W2414264365 @default.
• W2098188679 cites W4236639597 @default.
• W2098188679 cites W45522490 @default.
• W2098188679 doi "https://doi.org/10.1136/thx.52.6.535" @default.
• W2098188679 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/1758577" @default.
• W2098188679 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9227720" @default.
• W2098188679 hasPublicationYear "1997" @default.
• W2098188679 type Work @default.
• W2098188679 sameAs 2098188679 @default.
• W2098188679 citedByCount "101" @default.
• W2098188679 countsByYear W20981886792012 @default.
• W2098188679 countsByYear W20981886792013 @default.
• W2098188679 countsByYear W20981886792014 @default.
• W2098188679 countsByYear W20981886792016 @default.
• W2098188679 countsByYear W20981886792019 @default.
• W2098188679 countsByYear W20981886792023 @default.
• W2098188679 crossrefType "journal-article" @default.
• W2098188679 hasAuthorship W2098188679A5003864064 @default.
• W2098188679 hasAuthorship W2098188679A5006832289 @default.
• W2098188679 hasAuthorship W2098188679A5011519571 @default.
• W2098188679 hasAuthorship W2098188679A5030603878 @default.
• W2098188679 hasAuthorship W2098188679A5036017418 @default.
• W2098188679 hasAuthorship W2098188679A5044409997 @default.
• W2098188679 hasAuthorship W2098188679A5066056972 @default.
• W2098188679 hasAuthorship W2098188679A5084335551 @default.
• W2098188679 hasAuthorship W2098188679A5089109471 @default.
• W2098188679 hasAuthorship W2098188679A5091663221 @default.
• W2098188679 hasBestOaLocation W20981886791 @default.
• W2098188679 hasConcept C126322002 @default.
• W2098188679 hasConcept C142724271 @default.
• W2098188679 hasConcept C204787440 @default.
• W2098188679 hasConcept C27081682 @default.
• W2098188679 hasConcept C2776042228 @default.
• W2098188679 hasConcept C2776136866 @default.
• W2098188679 hasConcept C2776804153 @default.
• W2098188679 hasConcept C2779871671 @default.
• W2098188679 hasConcept C2781018748 @default.
• W2098188679 hasConcept C2909086917 @default.
• W2098188679 hasConcept C42219234 @default.
• W2098188679 hasConcept C71924100 @default.
• W2098188679 hasConceptScore W2098188679C126322002 @default.
• W2098188679 hasConceptScore W2098188679C142724271 @default.
• W2098188679 hasConceptScore W2098188679C204787440 @default.
• W2098188679 hasConceptScore W2098188679C27081682 @default.
• W2098188679 hasConceptScore W2098188679C2776042228 @default.
• W2098188679 hasConceptScore W2098188679C2776136866 @default.
• W2098188679 hasConceptScore W2098188679C2776804153 @default.
• W2098188679 hasConceptScore W2098188679C2779871671 @default.
• W2098188679 hasConceptScore W2098188679C2781018748 @default.
• W2098188679 hasConceptScore W2098188679C2909086917 @default.
• W2098188679 hasConceptScore W2098188679C42219234 @default.
• W2098188679 hasConceptScore W2098188679C71924100 @default.
• W2098188679 hasIssue "6" @default.
• W2098188679 hasLocation W20981886791 @default.
• W2098188679 hasLocation W20981886792 @default.
• W2098188679 hasLocation W20981886793 @default.
• W2098188679 hasLocation W20981886794 @default.
• W2098188679 hasOpenAccess W2098188679 @default.
• W2098188679 hasPrimaryLocation W20981886791 @default.
• W2098188679 hasRelatedWork W1524634645 @default.
• W2098188679 hasRelatedWork W155366199 @default.
• W2098188679 hasRelatedWork W1795103282 @default.
• W2098188679 hasRelatedWork W1983715275 @default.
• W2098188679 hasRelatedWork W2006845954 @default.
• W2098188679 hasRelatedWork W2010350605 @default.
• W2098188679 hasRelatedWork W2060330127 @default.
• W2098188679 hasRelatedWork W2075130051 @default.
• W2098188679 hasRelatedWork W2390393958 @default.
• W2098188679 hasRelatedWork W3027296839 @default.

• next